ZIMMER SELLS 7,500 NEXGEN KNEE SYSTEMS IN FIRST 10 MONTHS ON MARKET;FIRM'S 1995 SALES TO HIT $1.15 BIL.; BMS TAKING CHARGE OF $250-$300 MIL.
This article was originally published in The Gray Sheet
Executive Summary
Bristol-Myers Squibb's Zimmer subsidiary sold 7,500 NexGen knee prostheses as of November, the company says. Based on the product's $3,500-$4,400 price, NexGen generated revenue in the range of $26-33 mil. in its first 10 months on the market.